ReviewDiscover oncology2025
Current strategies and novel immunotherapeutic approaches for overcoming immune resistance in glioblastoma.
Review in Discover oncology, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 8 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
8 citing papers in PubMed.
- Reprogramming Autophagy to Strengthen Antitumour Immunity: Advances in Immunotherapeutic Strategies.Immunology · 2026Review
- Artificial Intelligence in Veterinary Neurology: Comparative Insights From Human Medicine and Cross-Species Technology Transfer.Veterinary medicine and science · 2026Review
- Microbiota-Neuroinflammation Crosstalk in Primary Brain Tumors: Focus on Glioblastoma.Brain and behavior · 2026Review
- Therapeutic Potential of Ginger Rhizomes (Zingiber officinale) on Leukemia.Biotechnology and applied biochemistry · 2026Review
- Extracellular vesicles as therapeutic agents for retinal ganglion cell degeneration: current challenges and future prospects.International ophthalmology · 2026Review
- Dual-Function Lipid-Based Nanovector Strategy for Glioblastoma Immunotherapy: STING Activation and M1 Microglia Polarization.Drug development research · 2026Review
- Extracellular Vesicle-Associated miRNAs in Glioblastoma: Mechanisms, Biomarkers, Therapies, and Links to Neurodegeneration.Cancers · 2026Review
- Engineered exosomes for targeted glioma therapy: overcoming the blood-brain barrier with nature-inspired nanocarriers.Discover nano · 2026Review
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
10 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Glioblastoma (GBM) is the most aggressive primary malignant brain tumor, characterized by rapid proliferation, extensive invasion, and significant genetic heterogeneity. Despite the availability of standard treatments such as surgical resection, radiotherapy, and chemotherapy, the prognosis for GBM patients remains poor, with a median survival of approximately 15 months. Recent advances in immunotherapy have introduced innovative approaches aimed at leveraging the immune system to specifically target and eliminate GBM cells. These strategies include cytokine-based therapies, immune checkpoint inhibitors, chimeric antigen receptor (CAR) T-cell and natural killer (NK) cell therapies, RNA-based immunotherapies, and nanoparticle-mediated drug delivery systems. Furthermore, emerging technologies such as CRISPR/Cas9 gene editing, exosome-based delivery, STING pathway activation, and AI-guided personalized treatment have shown promise in overcoming the immunosuppressive tumor microenvironment and enhancing therapeutic efficacy. This review provides a comprehensive overview of these cutting-edge approaches, discussing their mechanisms, clinical potential, current limitations, and future directions for the development of more effective immunotherapies for GBM.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.